Curriculum Vitae

Dowdy Jackson, Ph.D.

Email: *dowdyjackson@jackson-consulting-group.com*

Education

University of California Los Angeles	B.S. Biology
California State University Dominguez Hills	M.A. Biology
Northwestern University	Ph.D. BMBCB
University of California San Francisco	Amgen Postdoctoral Fellow/UNCF-Merck Postdoctoral Fellow (Dr. Douglas Hanahan)

Executive Summary

Drug development experience:

I have over 20 years of experience developing therapeutics for oncology patients at large pharmaceutical companies and medium to small biotechnology companies.

I have experience developing small molecule inhibitors, antibody drug conjugates (ADCs), immune-stimulating antibody conjugates (ISACs) and bispecific antibodies.

I have experience preparing documents for regulatory submissions, such as INDs, NDAs and BLAs. I have provided responses and attended meetings with regulatory agencies, such as the FDA. I have experience preparing regulatory submissions in the US, Europe, China and Australia.

My team provided the *in vitro* preclinical data for Enfortumab vedotin (PADCEV), which was approved by the FDA in 2019 for patients with locally advanced or metastatic urothelial cancer.

Leadership experience:

I have led several multifunctional and multinational project teams. The teams have ranged in size from small project teams, consisting of biologists, chemists and *in vivo* pharmacology experts to evaluate potential drug candidates to larger teams consisting of clinical teams, CMC teams, and project managers to prepare for clinical development. I have led teams where team members were in the US, China, Korea and Europe.

I have led two small molecule projects from clinical development to IND submission and clinical development. I have led and provided guidance for several ADCs from preclinical development to IND submission, clinical development and approval.

I have successfully managed academic and corporate collaborations, which have resulted in publications in peer reviewed journals, poster presentations, patents, and the in-licensing of key technologies to enhance the drug development pipeline. I have managed the research activities at various CROs ranging from *in-vitro* assays and enzyme assay development to *in vivo* efficacy studies and pharmacokinetic studies.

I serve as a mentor and advocate for my direct reports. I encourage them to lead projects and help them prepare realistic timelines and appropriate go/no go decision for their projects. I help them prepare for presentations to senior management and external meetings. I also encourage them to prepare manuscripts and submit them to peer reviewed journals.

I have managed scientists ranging from recent college graduates, recent PhDs to experienced scientists. I am interested in ensuring that talented non-Ph.D. scientists are given an opportunity to be promoted into career tracts that might not have been available to them. During my time at Agensys, I developed a program that provided an opportunity for talented non-PhD scientists to be promoted to an entry level PhD scientist promotion track.

Biomarkers and Translational leadership experience:

Antibody drug conjugates:

I led the effort to develop assays to evaluate the PK/PD relationship between the tumor PK of ADCs and the induction and duration of apoptotic cell death in human tumor xenograft models. I worked with the team at Meso Scale Discovery (MSD) to develop the assays.

I led the effort to understand the relationship between receptor density and ADC activity to understand the receptor density required to develop effective ADCs.

I led the effort to develop the PK assay to evaluate the PK properties of the Her2 ADC (IBI354) during preclinical and clinical development.

I led the development of assays to assess the potential resistance mechanisms to topoisomerase I inhibitors. These assays would help determine if patient tumors would potentially respond to an ADC using a topoisomerase I inhibitor.

Diarrhea is a major side effect of topoisomerase I inhibitors. I led the effort to identify assays to aid the chemistry team in developing topoisomerase I inhibitors to reduce this side effect.

Immunotherapy:

Collaborated with the team at Bolt Biotherapeutics to develop assays to assess the induction of cytokines to address potential CRS for the Claudin 18.2 Immune stimulating antibody conjugate (ISAC).

As the project leader, I guided the evaluation and development of an anti-CD3 Fab-folate bispecific antibody (BiTE) and the assessment of biomarkers for activity and the induction of CRS.

I led the effort to evaluate which ADC payloads induced immunogenic cell death (ICD) and the markers associated with ICD.

Professional Experience

Innovent Biologics, August 2021 – February 2024
Executive Director of ADC Biology

- Establish and implement the ADC strategy for the US and China markets.
- Revised the ADC pipeline to make it a competitive pipeline and mitigate risk.
- Develop and lead the ADC teams in the US and China.
    - Served as the project leader for IBI354 (Her2 ADC) currently in phase 1/2.
- Worked with business development to identify and develop collaborations, acquisitions and/or in-licensing opportunities to develop a robust ADC pipeline.
- Led two major collaborations with China and US based biotechnology companies.
    - Bolt Biotherapeutics: Novel TLR7/8 agonist evaluation and development.

- Serve as a mentor and aid in the career develop of scientists at Innovent Biologics.

TB Alliance, January 2019 – August 2021
Director of Biology

- Establish the criteria and lead the efforts to evaluate and identify novel small molecule inhibitors against essential enzymes to treat multi-drug resistant Tuberculosis (TB).
- Work with CROs, biotechnology companies and academic labs to preform critical studies to evaluate the inhibitors.
- Work with academic collaborators and international agencies to identify new therapeutic targets using CRISPR and other technologies.
- Work with academic collaborators to develop new treatment regimens for multi-drug resistant TB.
- Used DNA encoded libraries (DEL) and artificial intelligence (AI) to identify new chemical matter for TB targets, including kinase targets.

Ambrx, Inc, February 2017 – September 2018
Director of Biological Sciences

- Ensured that our group performed the necessary experiments, within the agreed timelines, to develop and evaluate novel ADC payloads/linkers, mouse, human and humanized antibodies and antibody drug conjugates (ADCs).
- Responsible for the target identification and target validation efforts using various methods, which includes genomics database mining.
- Development and evaluation of bispecific antibodies against immuno-oncology targets.

- Led the CD3-Folate bispecific project (BiTE). This project has successfully optimized a bispecific antibody, which selectively kills Folate receptor-α expressing cells. This project is advancing through our pipeline and is moving towards clinical development.
    - Oral presentation: "Optimization of a Bispecific Anti-CD3 Antibody-Folate Bio-Conjugate for the Treatment of Ovarian Cancer" PEGS-Boston 2018
- Led the non-clinical development of the PSMA ADC project, which is in Phase I/II clinical development.

Agensys, Inc, March 2011 – February 2017
Associate Director and Antibody Drug Conjugate Biology Group Leader

- Evaluated new ADC technologies, including novel cytotoxic payloads and linkers.
    - Developed *in vitro* assays to address potential drug resistance mechanisms and identify payloads that killed drug resistant cell lines.
    - Led the biology efforts to identify a novel Auristatin payload (AGL-0182-30) which is the payload for the anti-FLT3 ADC (AGS62P1) now in clinical development.
- Evaluated in-house ADCs using *in-vitro* and *in-vivo* studies.
- Developed methods to explore the mechanism of action of the ADCs and the critical pathways required for ADC activity.
- Led the ADC research project teams from preclinical development through clinical development.
- Developed the cell lines and led the *in vitro* evaluation to support the Nectin4 ADC (Enfortumab vedotin) project. Enfortumab vedotin was approved by the FDA on December 18th 2019.
- Wrote the collaboration agreement between Agensys and Ambrx and led the joint project team. The result of this collaboration resulted in Agensys agreeing to make an upfront payment of 15 million dollars (USD) as well as up to 285 million dollars (USD) in potential near and long-term research, development, regulatory and sales based milestones for an undisclosed number of targets for ADCs in oncology.
    - First author on the peer-reviewed publication resulting from the collaboration between Agensys and Ambrx.

- Supervised the development and evaluation of knob-in-hole bispecific antibodies (BiTEs) for four tumor targets.
- Established the Agensys seminar speaker program where we invited leading experts in oncology to discuss their work.
- Led the effort to develop the Agensys thesis program where non-PhD level scientists could be promoted to positions in the PhD scientist tract by completing an independent research project. This program was implemented and celebrated our first graduate.

Medimmune, Inc. 2006-2011
Group Leader/Project Leader

Led a group, within the Oncology department, that is responsible for the following activities:

EphA2 ADC Project (Medi-547)

- Led the preclinical development of an antibody drug conjugate against EphA2.
- Responsible for the *in-vitro* and *in-vivo* evaluation of the EphA2 antibody drug conjugate.
- Led the team to write and successfully file an IND. Initiated the phase I clinical trial.

Additional Antibody Drug Conjugate Programs

- Led additional antibody drug conjugate projects.

Cell Surface Oncology Target Identification, Biomarkers and *In-vivo* Imaging

- Collaborated with several teams to identify and evaluate cell surface oncology targets.
- Evaluated potential combination partners, biomarkers for drug activity and *in-vivo* imaging.

Development of a small molecule inhibitor against HSP90

- Co-leader of the preclinical development of a small molecule inhibitor against HSP90.
- Responsible for developing and supporting the *in-vitro* and *in-vivo* characterization of the HSP90 inhibitor (IPI-504), via co-development with Infinity Pharmaceuticals.
- Submitted an IND and initiated clinical trials in collaboration with Infinity Pharmaceuticals.

Novartis Institutes for Biomedical Research *2003- 2006*
Lab Head

- Led a lab in the *In-vivo* Oncology Pharmacology group. My group of *in-vivo* pharmacologists performed the *in-vivo* studies for the following projects I lead.

Development of a small molecule inhibitor against FAK

- Program leader for the development of a series of small molecule inhibitors against focal adhesion kinase (FAK).
- My laboratory was responsible for all of the preclinical development and evaluation of the inhibitors.
    - Identified a promising lead series of inhibitors, which show inhibition of FAK and IGF-1R, *in vivo* tumor efficacy and has an acceptable toxicity/safety profile.

- My laboratory was also responsible for establishing and supporting all collaborations with academic and contract laboratories. Our team consisted of scientists from the United States of America and Japan.

***In vivo* target validation using RNAi**

- Led a team of scientists in developing techniques to validate oncology targets *in vivo* using RNAi. We used a variety of techniques, which included developing tumor cell lines to regulate the expression of various shRNAs *in vivo*. We also explored systemic delivery methods for siRNAs in various tumor models.

Development of novel models to study tumor angiogenesis

- My laboratory developed novel methods and models to study tumor angiogenesis *in vivo*. We developed a nude mouse version of the Tie2- GFP transgenic mouse, which has been used to gain a better understanding of angiogenesis in the tumor environment.

Pharmacia Corporation (now Pfizer Corporation) ***1998-2003***
Scientist I/II

Development of small molecule inhibitors of integrins.

- Performed *in vitro* studies to identify $\alpha_v\beta_3$ peptidomimetics, which inhibit $\alpha_v\beta_3$ mediated interactions with specific extracellular matrix proteins.
- Evaluated $\alpha_v\beta_3$ peptidomimetics were efficacious in several xenograft and syngeneic tumor models.
- Developed methods to detect inhibition of $\alpha_v\beta_3$ interactions with its extracellular matrix protein *in-vivo*. Our $\alpha_v\beta_3$ peptidomimetic entered phase I clinical trials.
- Coauthored a paper that explored the use of $\alpha_v\beta_3$ targeted nanoparticles using magnetic resonance imaging (MRI). We chose to use MRI to detect $\alpha_v\beta_3$ interactions because it provides us with a simple, non-invasive means to identify patients that express $\alpha_v\beta3$ in their tumors and/or vasculature.
- Led a group of scientists in the development of methods to detect changes in the $\alpha_v\beta_3$ signaling cascade *in-vivo*, in the hopes of identifying a biomarker.

Development of MetAP2 inhibitors

- Led a 25 member team that identified small molecule inhibitors of MetAP2, which were chemically distinct from known MetAP2 inhibitors.
- Coordinated the project's research efforts across several departments, which included structural biologists, enzymologists, protein biochemists, medicinal chemists, *in-vivo* biologists and pharmacologists.
- Devised the testing scheme, milestone/timelines, outlined the target validation plan and updated senior management on the progress of the project. In addition to identifying selective, small molecule inhibitors of MetAP2, we identified and characterized a novel member of the MetAP family.

- Coordinated the writing and submission of manuscripts to peer reviewed journals, and patent filings.

Identification of proteins regulated during tumor angiogenesis

- Responsible for planning and executing the strategy around the utilization of tumor models and unique transgenic mice, in order to identify genes that are regulated during tumor angiogenesis.
- My team identified several genes that were selectively expressed by tumor endothelial cells. In an effort to validate our DNA microarrays.
- Successfully identified genes that were selectively expressed by endothelial cells *in-vitro*.
- Led the functional validation studies of these genes and patent filing.

Postdoctoral Fellowship (University of California San Francisco – Dr. Douglas Hanahan's laboratory)

- Discovered that endothelial cells selectively expressed EphA2, while the insulinoma cells and the endothelial cells expressed the ligand, EphrinA1.
- Collaborated with Dr. Jin Chen at Vanderbilt University and showed that inhibition of the EphA2 receptor tyrosine kinase, in the RipTAg model, inhibited tumor angiogenesis and tumor growth.

Doctoral Studies (Northwestern University – Dr. Daniel Linzer)

- Studied placental development in the mouse. My research focused on two placental proteins named proliferin (PLF) and proliferin related protein (PRP).
- Discovered, in collaboration with Drs. Olga Volpert and Noel Bouck (Northwestern University), that PLF functioned as the major pro-angiogenic factor produced by the mouse placenta while PRP is a potent inhibitor of PLF and basic fibroblast growth factor (bFGF) induced angiogenesis.

Fellowships and Awards

Minority Biomedical Research Support (MBRS)	1989-1990
Constance Campbell Award in Reproductive Endocrinology	1994
Amgen Postdoctoral Fellowship	1996-1998
Merck/UNCF Postdoctoral Fellowship	1997-1998

Memberships

American Association for the Advancement of Science (AAAS)
American Society of Cell Biology (ASCB)
American Association for Cancer Research (AACR)

Computer Skills

- Proficient in C, C++, Pascal, and Visual Basic.
- Learning Python.
- Machine learning (ML) and artificial intelligence (AI) methods
- Familiar with several windows, apple and unix based operating systems.
- Familiar with the c-shell environment and have some experience in c-shell programming.
- Proficient using several programs including MS Word, Excel, Powerpoint, Spotfire and Adobe photoshop

Editorial and Reviewing Activities

Adhoc Manuscript Reviews
Bioconjugate Chemistry
Biotechnology and Applied Biochemistry
Clinical Cancer Research
Current Cancer Drug Targets
Cancer Research
Science
Nature
Endocrinology
Journal of Cellular Biochemistry
Toxicology Mechanisms and Methods

Grant Reviews
Washington University/Pharmacia Research Grant Program

Teaching Assignments

Montgomery College (Germantown, MD) 2006

- Taught a course entitled "Nucleic Acid Methods" in the biotechnology program. The course consisted of a lecture and laboratory. The students learned nucleic acid chemistry, DNA/RNA isolations and basic molecular biology techniques.

Middlesex Community College (Lowell, MA) 2004

- Taught a biochemistry course to students enrolled in the biotechnology program. The class is a basic biochemistry course, which provides the students with a broad view of the subject.

Florissant Valley Community College (Florissant, MO) 2002

- Developed and taught a course to students enrolled in the biotechnology program on how to use DNA microarrays. The class lectures were organized to

provide the students with basic knowledge of both cellular and molecular biology. The laboratory component of the class provided the students with hands on experience on how to isolate and purify total and mRNA from cells *in-vitro*, how to convert their mRNA samples into cDNA, how to incorporate cy3 and cy5 dyes into their cDNAs for use in DNA microarray analysis and how to analyze data from their microarray experiments. The students also learned basic cloning and mammalian cell culture techniques.

Invited Lectures and Presentations

ADC Target Selection Summit, December 2023 (Served as the meeting chair)
"Clarifying What Level of Expression Is Actually Good for ADC Target Selection?"

ADC Target Selection Summit, December 2022
"Evaluating Lessons Learnt from ADC Target Selection"

US Antibody Engineering Xchange Philadelphia, September 2018
"Redefining Preclinical Studies To Reflect The Clinical Reality"

US Antibody Engineering Xchange Philadelphia, March 13, 2018
"Redefining Preclinical Studies To Reflect The Clinical Reality"

The Company of Biologists' Workshop West Essex, UK 2016
"Rethinking Cancer"

California State University, San Marcos 2014
"The Development of Therapeutic Antibodies"

Mount Sinai School of Medicine Translational Science Course 2013
"The Development of Therapeutic Antibodies"

Molecular Med Tri-con 2011
"Early Stage Antibody Drug Conjugate Development, preparations for the clinic."

Antibody Drug Conjugate World Summit 2010
"Early Stage Antibody Drug Conjugate Development, preparations for the clinic."

Ephs and Ephrins in Cancer 2010
"The development of an EphA2 antibody drug conjugate: From bench to the clinic."
* Session chairman.

Discovery on Target 2009
"Development of an Antibody Drug Conjugate Targeting The EphA2 Receptor Tyrosine Kinase"

American Association for Cancer Research 2007
"A Humanized EphA2-Auristatin Conjugate Antibody Inhibits Tumor Growth *In vivo*"

American Society of Clinical Oncologists 2006
"A Novel Low Molecular Weight Inhibitor of Focal Adhesion Kinase and Insulin-like Growth Factor-1 Receptor, TAE226, Inhibits Glioma Growth."

Gordon Conference (Angiogenesis and Microcirculation) 2001
"Methionine Aminopeptidase 2 (MetAP2): A novel target for antiangiogenic therapy."

Howard University 2000
"Using DNA microarrays to analyze genes involved in angiogenesis."

Vanderbilt University 2000
"Using DNA microarrays to study angiogenesis."

Oncology Day (Pharmacia, Nerviano, Italy) 2000
"MetAP2's role in angiogenesis."

Gordon Conference (Angiogenesis and Microcirculation) 1999
"The identification of novel genes and their role in angiogenesis."

Endocrine Society 1995
"Proliferin and Proliferin regulated protein are involved in placental angiogenesis."

Patents

Pub. No.: WO/2008/157490 International Application No.: PCT/US2008/067114
Publication Date: 24.12.2008 International Filing Date: 16.06.2008
Title: SYNERGISTIC TREATMENT OF CELLS THAT EXPRESS EPHA2 AND ERBB2

Pub No.: EP4087613A1
Application filed by Cytomx Therapeutics Inc 2021-01-06
Publication of EP4087613A1 2022-11-16
Title: Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof

Pub No.: WO2021142029A1
Application filed by Cytomx Therapeutics, Inc. 2021-07-15
Publication of WO2021142029A1 2021-01-06
Title: Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof

---

Peer Reviewed Journal Publications

1. **Dowdy Jackson**. Bispecific ADCs Book chapter in preparation) 2024
2. **Dowdy Jackson**. The highs, lows and resurgence of ADCs (Under review) 2024
3. **Dowdy Jackson**, et. al. Trastuzumab meditecan: An Antibody Drug Conjugate targeting Her2 that has robust bystander activity and an improved preclinical safety profile compared to Trastuzumab deruxtecan. (In preparation) 2024
4. Feng Tian, **Dowdy Jackson**, Yun Bai Site specific antibody drug conjugate. (Chapter 10); *Innovations for Next-Generation Antibody-Drug Conjugates*, Editors: Damelin, Marc (Ed.); Springer 2018.
5. **Dowdy Jackson** and David Stover. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates. *Pharm Res*. 2015 Nov;32(11):3458-69
6. **Jackson D**, Atkinson J, Guevara CI, Zhang C, Kery V, et al. (2014) In Vitro and In Vivo Evaluation of Cysteine and Site Specific Conjugated Herceptin Antibody-Drug Conjugates. *PLoS ONE* 9(1): e83865. doi:10.1371/journal.pone.0083865
7. Zhan Xiao**, Dowdy Jackson** and David A. Tice. EphA2 Immunoconjugate (Chapter 14); Pages 241-254 *Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications*; edited by Gail Lewis Phillips; Springer; 2013
8. Jeong-Won Lee, Eun Ji Nam, Alpa M Nick, Rebecca L Stone, Hee-Dong Han, Mian M.K. Shahzad, Hye-Sun Kim, Lingegowda S. Magala, Nicholas B. Jennings, Shenlan Mao, John Gooya, **Dowdy Jackson**, Robert Coleman, Anil K Sood. EphA2 Targeted Chemotherapy Using An Antibody Drug Conjugate In Endometrial Carcinoma. *Clin Cancer Res.* 2010 May 1;16(9):2562-70
9. Guanglei Zhuang, Dana M. Brantley-Sieders, David Vaught, Jian Yu, Lu Xie, Sam Wells, **Dowdy Jackson**, Rebecca Cook, Carlos Arteaga and Jin Chen. A Determining Role of The EphA2 Receptor Tyrosine Kinase In Resistance To Trastuzumab Therapy. *Cancer Res*. 2010 Jan 1;70(1):299-308. Epub 2009 Dec 2
10. Ching Ching Leow, Jon Chesebrough, Karen T. Coffman, Christine A. Fazenbaker, John Gooya, David Weng, Steve Coats, **Dowdy Jackson**, Bahija Jallal, Yong Chang. Anti-Tumor Efficacy of IPI-504, A Selective Hsp90 Inhibitor Against HER2+ Human Xenograft Models As A Single Agent And In Combination With Trastuzumab or Lapatinib. *Mol Cancer Ther*. 2009 Aug;8(8):2131-41. Epub 2009 Aug 11.
11. Jeong-Won Lee, Seung Wook Kim, Mian M.K. Shahzad, Hee-Dong Han, Lingegowda S. Mangala, Alpa. Nick, Chunhua Lu, Rosemarie Schmandt Hye-Sun Kim, John Gooya, Christine Fazenbaker, **Dowdy Jackson**, David Tice, Charles N. Landen Jr, Robert L. Coleman, Anil K. Sood. Molecularly Targeted Chemotherapy Using a Novel EphA2 Immunoconjugate in Ovarian Carcinoma. *J Natl Cancer Inst*. 2009 Jul 29
12. **Dowdy Jackson**, John Gooya, Shenlan Mao, Krista Kinneer, Linda Xu, Margarita Camara, Christine Fazenbaker, Ryan Fleming, Sudha Swamynathan, Damon Meyer, Peter D. Senter, Changshou Gao, Herren Wu, Michael Kinch, Steven

Coats, Peter A. Kiener, David A. Tice. A Human Antibody Drug Conjugate Targeting EphA2 Inhibits Tumor Growth In vivo. *Cancer Research* 68, 9367-9374, November 15, 200

13. Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, Coffman K, **Jackson D**, Bruckheimer E, Muraoka-Cook RS, Chen J. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. *J Clin Invest*. 2007 Jan;118(1):64-78.
14. Wiederschain D, Chen L, Johnson B, Bettano K, **Jackson D**, Taraszka J, Wang YK, Jones MD, Morrissey M, Deeds J, Mosher R, Fordjour P, Lengauer C, Benson JD. Contribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesis. *Mol Cell Biol*. 2007 Apr 23
15. Qing Shi, Anita B. Hjelmeland, Stephen T. Keir, Sarah Wickman, Guanghong Wu**, Dowdy Jackson,** Osamu Ohmori, Darell D. Bigner, Henry S. Friedman, Jeremy N. Rich. A Novel Low Molecular Weight Inhibitor of Focal Adhesion Kinase and Insulin-like Growth Factor-1 Receptor, TAE226, Inhibits Glioma Growth**.** *Mol Carcinog*. 2007 Jan 11; : 17219439
16. Liu TJ, LaFortune T, Honda T, Ohmori O, Hatakeyama S, Meyer T, Jackson D, de Groot J, Yung WK. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. *Mol Cancer Ther.* 2007 Apr;6(4):1357-67.
17. N. Cheng, D. Brantley, H. Liu, W. Fanslow, D. Cerretti, **D. Jackson**, and J. Chen. Inhibition of VEGF-dependent multi-stage carcinogenesis by soluble EphA receptors. *Neoplasia* 2003 Sep-Oct;5(5):445-56.
18. Dana M. Brantley, Nikki Cheng, Erin J. Thompson, Qin Lin, Rolf A. Brekken, Philip E. Thorpe, Rebecca S. Muraoka, **Dowdy Jackson**, Charles Lin, and Jin Chen EphA Class Receptor Tyrosine Kinases Regulate Tumor Angiogenesis. *Oncogene*. 2002 Oct 10;21(46):7011-26.
19. Anderson SA, Rader RK, Westlin WF, Null C, **Jackson D**, Lanza GM, Wickline SA, and Kotyk JJ Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. *Magn Reson Med*. 2000 Sep;44(3):433-9
20. **Jackson D** and Linzer DI Proliferin transport and binding in the mouse fetus. *Endocrinology*. 1997 Jan;138(1):149-155
21. Volpert O, **Jackson D**, Bouck N and Linzer DI The insulin-like growth factor II/mannose 6-phosphate receptor is required for proliferin-induced angiogenesis. *Endocrinology*. 1996 Sep;137(9):3871-6
22. **Jackson D**, Volpert O, Bouck N and Linzer DI Stimulation and inhibition of angiogenesis by placental proliferin and proliferin related protein. *Science*. 1994 Dec 2;266(5190):1581-4
23. **Jackson D** and Henriksen KD Structural analysis of protein folding. *UCLA Undergraduate Science Journal* 1985 1(1): 104

Collaborations

I have been the point person for several collaborations with academic and industry partners.

1. The collaboration with Dr. Jin Chen (Vanderbilt University)
Dr. Chen and my lab at MedImmune collaborated on the importance of the EphA2 receptor in cancer. This collaboration lasted for several years and resulted in the three peer reviewed publications and a patent application.

2. The collaboration with Dr. Anil Sood (University of Texas Southwestern)
Dr. Sood's lab and my lab at MedImmune collaborated on the evaluation of the first anti-EphA2 antibody drug conjugate for the treatment of ovarian cancer. This collaboration lasted for several years and resulted in two peer reviewed publications.

3. The collaboration with Dr. Richard Finn (UCLA)
Dr. Finn's lab and my lab at Agensys, Inc collaborated on the evaluation of the cytotoxicity of several small molecule inhibitors. This collaboration resulted helping our company develop a better understanding of the cytotoxic profile of our inhibitors.

4. The collaboration with Ambrx, Inc.
I led the collaboration between Agensys, Inc and Ambrx, Inc. We evaluated Ambrx's site specific antibody technology for use as an ADC. The results of the collaboration resulted in Agensys licensing Ambrx's technology, with an up-front payment of 15 million dollars. We have begun the clinical evaluation of our first site-specific ADC using Ambrx's technology (AGS62P1). We published our results in a peer-reviewed journal.

5. Collaboration with Schrodinger, Inc.
I was leading a collaboration between TB Alliance and Schrodinger, Inc where we are using machine learning and artificial intelligence to identify and optimize novel anti-tuberculosis drugs from DNA encoded libraries.

6. Collaboration with a Chinese biotechnology company
I am leading the collaboration between Innovent Biologics and a Chinese biotechnology where we are using their ADC linker/payloads and developing their Her2 ADC.

7. Collaboration with Bolt Biotherapeutics
I am leading the collaboration between Innovent Biologics and Bolt Biotherapeutics where we are evaluating their ISAC ADC technology on our Claudin18.2 antibody. We presented a poster at the 2023 SITC meeting.

Title: 1147-D Preclinical characterization of a novel claudin 18.2 targeting-ISAC with robust potency and acceptable safety profile.
https://investors.boltbio.com/static-files/ea1bb46b-d8ca-4dc9-a521-80faba65b9ca